Repurposing Bazedoxifene for chemoprevention in pre-invasive pancreatic cancer IPMN

PROJECT NARRATIVE We have previously identified FDA-approved Bazedoxifene as an inhibitor of the IL-6 signaling axis, a major oncogenic promoter of pancreatic cancer. Here we aim to investigate the feasibility of repurposing this well-tolerated medication as a chemopreventive therapy for patients who are at high-risk for pancreatic cancer in preclinical models. The success of our application can be immediately translated to benefit patients who can be identified as high-risk but are not sufficiently managed by current care (i.e. patients with detectable premalignant lesions, chronic pancreatitis, familial mutations).